3 Stopping anticoagulation after ablation What is the clinical and cost effectiveness of stopping anticoagulation in people whose atrial fibrillation has resolved after ablation? [2021] For a short explanation of why the committee made the recommendation for research, see the rationale on stopping anticoagulation. Full details of the evidence and the committee's discussion are in evidence review H: discontinuing anticoagulation in people whose atrial fibrillation has resolved. 4 Stopping anticoagulation after resolution of postoperative atrial fibrillation What is the clinical and cost effectiveness of stopping anticoagulation in people whose postoperative atrial fibrillation after cardiac surgery has resolved? [2021] For a short explanation of why the committee made the recommendation for research, see the rationale on stopping anticoagulation. Full details of the evidence and the committee's discussion are in evidence review H: discontinuing anticoagulation in people whose atrial fibrillation has resolved. 5 Cognitive behavioural therapy for people with atrial fibrillation What is the clinical and cost effectiveness of cognitive behavioural therapy compared with usual care for people with newly diagnosed atrial fibrillation? [2014] 6 Rate-control drug treatment for people aged 75 and over with atrial fibrillation What is the comparative effectiveness of the 3 main drug classes used for rate control (beta-blockers, calcium-channel blockers and digoxin) in people aged 75 and over with atrial fibrillation in controlling symptoms, improving quality of life and reducing morbidity and mortality? [2014] 7 Stroke risk assessment Can routine data from UK primary care databases clarify stroke risk in people with atrial fibrillation according to baseline risk factors and treatment? [2014] Rationale and impact These sections briefly explain why the committee made the recommendations and how they might affect practice. 